Get my own profile
Public access
View all14 articles
1 article
available
not available
Based on funding mandates
Co-authors
- Bret SellmanDirector, Discovery Microbiome, AstraZenecaVerified email at astrazeneca.com
- Antonio DiGiandomenicoAstraZenecaVerified email at astrazeneca.com
- Jamese HilliardJanssen Pharmceutical R&DVerified email at its.jnj.com
- David R. ShermanProfessor and Chair, Microbiology, University of WashingtonVerified email at uw.edu
- Thomas FuerstUniversity of MarylandVerified email at umd.edu
- Geetha P. BansalVerified email at nih.gov
- Clifton E Barry IIINIAIDVerified email at niaid.nih.gov
- Nazzareno Dimasi, Ph.D.Senior Director, Head of Antibody Discovery & Engineering, Sanofi Biologics USAVerified email at sanofi.com
- Godfrey Jonah RaineyAlivaMab Discovery ServicesVerified email at alivamab.com
- Binh An DiepProfessor, UCSFVerified email at ucsf.edu
- Graham HatfullDepartment of Biological Sciences, University of PittsburghVerified email at pitt.edu
- Omari JonesMedimmuneVerified email at medimmune.com
- William SchwanProfessor of Microbiology, University of Wisconsin-La CrosseVerified email at uwlax.edu
- Melissa DamschroderDirector, R&D, AstraZenecaVerified email at astrazeneca.com
- Davide CortiSVP Antibody ResearchVerified email at humabs.ch
- D R VanDevanterCase Western Reserve University School of MedicineVerified email at case.edu
- Lloyd S. Miller, MD, PhDVice President, Immunodermatology, Janssen Research & DevelopmentVerified email at its.jnj.com
- Paul KubesUniversity of Calgary LSUVerified email at ucalgary.ca
- David N. McMurrayTexas A&M UniversityVerified email at tamu.edu
- Alan G. BarbourUniversity of California IrvineVerified email at uci.edu